@PredictaBiosciences

Susan’s @HealthTree story shows how deeper molecular testing transformed her multiple myeloma care — finding actionable insights standard tests missed, reducing invasive biopsies, and guiding better therapy choices. Why it matters: • Finds high‑risk markers & treatment‑relevant mutations • Enables less‑invasive blood monitoring • Helps avoid ineffective therapies Read Susan’s full story & learn about the early access program: healthtree.org/myeloma/commun…

Our team, led by François Aguet, is thrilled to share that GenoPredicta, our WGS test, shows 100% concordance between bone marrow and blood samples. We've pinpointed key resistance mechanisms impacting therapeutic targets like BCMA and GPRC5D—moving towards blood-based testing as a game changer for personalized myeloma care. Say goodbye to invasive biopsies. Catch us at our poster session and reach out to Daniel Auclair (Dan.Auclair@predictabiosciences.com) for meeting. 🗓️ Session: 803: Poster I 🗓️ Date: Dec 6, 2025 ⏰ Time: PM - PM 📍 Room: OCCC - West Halls B3-B4 📄 Pub Number: 2586

Our innovative blood test offers 100% concordance with traditional FISH-based tests and provides the same insights from a simple blood draw as from bone marrow. With GenoPredicta, clinicians can better detect key genetic alterations and guide personalized treatment plans. Learn more about at predictabiosciences.com.

Comprehensive characterization of multiple myeloma genomes from BM or PB w/ novel clinical assay [GenoPredicta] = ID of resistance mechanisms [Nov 3, 2025] @BrunoPaiva_UNAV et al @myelomaMD #ASH25 abs25-14403 PID2586 meetings-api.hematology.org/api/abstract/v… #mmsm #cagenome #oncopath #LiquidBiopsy

Circulating tumor cells (CTCs) improve risk stratification according to R2-ISS and the IMS-IMWG CGS in NDMM: An analysis from the european CTC consortium [Nov 3, 2025] @Dagostino_MD et al. #ASH25 abs25-12860 PID 364 meetings-api.hematology.org/api/abstract/v… #mmsm #cactc

Exciting news! @PredictaBio is attending #ASH25! We'll be presenting a poster showcasing GenoPredicta, our whole genome sequencing assay for myeloma—validated for both bone marrow and blood samples. Achieving 100% accuracy in detecting key genetic abnormalities and resistance mutations, it’s a big step toward earlier, personalized treatment. Visit us on 12/6 at Session 803: Poster I 5:30pm-7:30pm; OCCC - West Halls B3-B4 to join the discussion.

#Hematology #Diagnostics #PrecisionMedicine #Genomics #PredictaBiosciences

Predicta is redefining cancer diagnostics with GenoPredicta—a comprehensive, non-invasive whole genome sequencing test for multiple myeloma that works on blood or bone marrow. It helps clinicians make personalized treatment decisions faster and more accurately.

@FrancescoMaura4 @Thatquaratined1 @RahulBanerjeeMD @MyelomaTeacher @Myeloma_Society Predicta Biosciences already offer a WGS-based solution with the CLIA-approved GenoPredicta LDT. The test works with both bone marrow and peripheral blood samples and provides a comprehensive characterization of myeloma genomes. The test can be ordered at predictabiosciences.com/order

@Thatquaratined1 @RahulBanerjeeMD @MyelomaTeacher @Myeloma_Society The cost of WGS today is equivalent to 4-5 FISH probes. The problem are the infrastructures. But I am confident several providers will offer this service very soon making it accessible to most centers (at least in US).

Congratulations! Great work. How does this effect patient care today? #mmsm

🚀This Multiple Myeloma Awareness Month, we're dedicated to pushing the boundaries of innovation to improve patient outcomes. 🌟 Learn more about our commitment to cutting-edge solutions here at @PredictaBiosci . 🔬 #MyelomaAwarenessMonth

This week, our team gathered to focus on this year's goals. We are inspired and very excited about the work ahead and the impactful data we will generate to support both patients and clinicians.

Last night was above par as we celebrated the holiday spirit with our incredible team & had fun putting around! Celebrating the achievements of 2024 and excited for what the future holds. Wishing everyone a joyful holiday season and a prosperous year ahead!

🌟Welcome to Predicta Biosciences, @JulianMHess🌟 Julian joins Predicta Biosciences as Principal Computational Biologist, bringing expertise from @getz_lab @broadinstitute. We're thrilled to have him on board to advance our mission of impactful patient solutions!

Happy Thanksgiving from @PredictaBiosci! Our recent lunch was a wonderful opportunity to celebrate! During this season of gratitude, we want to thank our investors, clinicians, partners,& especially patients for your support. Wishing everyone a joyful & fulfilling holiday!

Aparna Raval, PhD, SVP of Translational Research, will attend the upcoming #ASH24. If you are interested in learning more about GenoPredicta and Immunopredicta platforms for multiple myeloma and other hematological malignancies, please email us info@predictabiosciences.com

A huge thank you to the BrightEdge - @AmericanCancer for hosting such impactful events & to Farnaz Bakhshi for moderating a fantastic session. It was a true pleasure to meet ACS President Karen Knudsen MBA, PhD. Thank you to @wilsonsonsini, for your support and sponsorship!

Thrilled to have been part of the recent Myeloma Committee, where Valentina Nardi delivered an insightful presentation on our work! A big thank you to @szusmani for the kind invitation. We are inspired by the innovative trials being conducted in the myeloma space!

Next week, we’re thrilled to be participating in events hosted by Brightedge - @AmericanCancer 🌟Monday: BrightEdge Entrepreneurs Pitch 🌟Tuesday: Join Kate Caves & industry leaders for a Panel Discussion, Fostering Founders & Entrepreneurs Across the Innovation Impasse